Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer [Phase 2]
This is a Phase 2 adjuvant trial evaluating dynamic biomarker–adjusted personalized therapy to optimize risk assessment and therapy response…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer [Phase 2]
Phase 2 clinical trial update evaluating correlation between clinical response and pathologic response in patients with early breast cancer.
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer [Phase 2]
Phase 2 trial comparing single-agent carboplatin to carboplatin plus everolimus in advanced triple-negative breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer [Phase 1]
Seagen's SEA-TGT (SGN-TGT) Phase 1 safety study in advanced cancers has been terminated. The study enrolled patients across multiple cancer …
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating trilaciclib in combination with sacituzumab govitecan-hziy for triple-negative breast cancer was terminated; resu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. [Phase 1]
Phase 1 clinical trial update for COM701, a PVRIG inhibitor, in adults with advanced solid tumors; the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) [Phase 2]
A Phase 2 neoadjuvant trial evaluating toripalimab in combination with docetaxel and carboplatin for localized triple-negative breast cancer…
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) [Phase 1, Phase 2]
This document is a completed Phase 1/Phase 2 clinical trial update for CAB-ROR2-ADC evaluating safety and efficacy in non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: CtDNA Based MRD Testing for NAC Monitoring in TNBC
This clinical trial update describes a study evaluating ctDNA-based minimal residual disease testing to monitor neoadjuvant chemotherapy in …
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
This clinical trial update reports on the assessment of complete pathologic response after neoadjuvant chemotherapy in breast cancer. The st…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors [Phase 1, Phase 2]
An update on the Phase 1/2 study of CYT-0851 in B-cell malignancies and advanced solid tumors, noting completion of Phase 1/2 cohorts.
-
CLINICAL_TRIALS trial_result · 2024-12-17Clinical Trial Update: A CR-UK Phase I Trial of LY3143921 [Phase 1]
Phase I trial update for LY3143921 sponsored by Cancer Research UK; the study is Active Not Recruiting and explores multiple cancer indicati…
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. [Phase 1]
A Phase I/Ib trial of NZV930 alone and in combination with PDR001 and/or NIR178 in patients with advanced malignancies has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-12-03Clinical Trial Update: OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease [Phase 2]
Phase 2 trial evaluating immune checkpoint inhibitor, capecitabine, or their combination as adjuvant therapy for triple-negative breast canc…
-
CLINICAL_TRIALS trial_result · 2024-12-03Clinical Trial Update: Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm [NA]
Completed clinical trial comparing biological features of small pN0 triple-negative breast cancers (≤10 mm) with larger tumors (pT1c/T2 ≤30 …
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety and efficacy of durvalumab in combination with neoadjuvant chemotherapy for localized Luminal B HER2-negat…
-
CLINICAL_TRIALS trial_result · 2024-11-19Clinical Trial Update: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers [Phase 1, Phase 2]
Clinical trial update for Galinpepimut-S in combination with pembrolizumab in selected advanced cancers (Phase 1/2) with completed status an…
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC [Phase 1]
A Phase 1 clinical trial evaluating the combination of olaparib and navitoclax in women with high-grade serous ovarian cancer and triple-neg…
-
CLINICAL_TRIALS trial_result · 2024-11-05Clinical Trial Update: First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours [Phase 1]
This clinical trial update reports the completion of a first-in-human Phase 1 study evaluating AZD8701 with or without durvalumab in adults …
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer [Phase 1]
Phase 1 study assessing safety and preliminary efficacy of ipatasertib plus atezolizumab with paclitaxel or nab-paclitaxel in locally advanc…
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. [Phase 1, Phase 2]
Clinical trial update reporting safety, pharmacokinetics, and efficacy findings for tinostamustine in patients with advanced solid tumors, i…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer [Phase 2]
A phase 2 study evaluating atezolizumab in combination with immunogenic chemotherapy for metastatic triple-negative breast cancer has comple…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial of JK08 for unresectable locally advanced or metastatic cancer conducted by Salubris Biotherapeutics is cur…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer [Phase 1]
Phase 1 trial evaluating the combination of alpelisib and enzalutamide in androgen receptor and PTEN positive metastatic breast cancer has c…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: PhI to Solid Tumors and PhII to Locally Advanced or mTNBC [Phase 1]
Laekna Limited reports a Phase 1 trial in solid tumors and a Phase 2 trial in locally advanced or metastatic triple-negative breast cancer; …